Cargando…
Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
Biologics are important treatment options for psoriasis; however, direct comparison of their efficacy, safety, and drug survival is insufficient in clinical practice. This retrospective single-center study aimed to compare the efficacy, safety, and drug survival of three commonly used psoriasis biol...
Autores principales: | Jung, Seung-Won, Lim, Sung Ha, Jeon, Jae Joon, Heo, Yeon-Woo, Choi, Mi Soo, Hong, Seung-Phil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139155/ https://www.ncbi.nlm.nih.gov/pubmed/35625795 http://dx.doi.org/10.3390/biomedicines10051058 |
Ejemplares similares
-
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023) -
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
por: Diels, J., et al.
Publicado: (2020) -
The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
por: Song, Eingun James, et al.
Publicado: (2020) -
Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020) -
Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
por: Elberdín, Laida, et al.
Publicado: (2022)